Voyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Wednesday, MarketBeat reports. The firm issued an outperform rating and a $15.00 target price on the stock.

Several other brokerages have also recently weighed in on VYGR. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Wedbush cut their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, August 20th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $17.43.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $8.07 on Wednesday. Voyager Therapeutics has a 1 year low of $5.71 and a 1 year high of $11.72. The firm has a market capitalization of $438.96 million, a PE ratio of -161.40 and a beta of 0.91. The stock has a fifty day moving average of $6.53 and a two-hundred day moving average of $7.70.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.20. The firm had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter last year, the company earned ($0.51) EPS. Equities research analysts predict that Voyager Therapeutics will post -1.44 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its holdings in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the period. Victory Capital Management Inc. increased its stake in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares during the period. SummerHaven Investment Management LLC raised its position in shares of Voyager Therapeutics by 2.5% during the second quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after acquiring an additional 1,921 shares during the last quarter. Hunter Perkins Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after acquiring an additional 2,025 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Voyager Therapeutics by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock valued at $925,000 after acquiring an additional 2,030 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.